Anti-smoking drug decreases alcohol consumption in heavy-drinking smokers

May 3, 2012 By Jennifer O'Brien

The smoking cessation drug varenicline significantly reduced alcohol consumption in a group of heavy-drinking smokers, in a study carried out by researchers at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco.

“Alcohol abuse is a huge problem, and this is a big step forward in identifying a potential new treatment,” said senior author Howard L. Fields, MD, PhD, professor of neurology and director of the Wheeler Center for the Neurobiology of Addiction at UCSF.

Study participants, who were seeking treatment for smoking and not for drinking, were randomly assigned to take either varenicline or a placebo. By the end of the study, participants assigned to varenicline had reduced their average number of drinks per week by 36 percent compared to those taking placebo.

The scientists found no correlation between the average number of drinks consumed per week by each subject and the average number of cigarettes they smoked, indicating that varenicline’s effects on drinking behavior were separate from its effects on smoking.

While they cautioned that additional study was needed to further examine potential side effects, the scientists said they are optimistic about the potential of varenicline as a treatment for heavy drinking. “The drug is already widely used by to help them quit,” said Fields. “Many heavy drinkers also smoke, and this study indicated that, in this group, varenicline was effective in reducing both the number of cigarettes smoked and the number of drinks consumed.”

Interestingly, in the study, varenicline did not change the number of times per week that subjects drank, said lead author Jennifer Mitchell, PhD, clinical project director at the Gallo Center and an adjunct assistant professor of neurology at UCSF. “People initiated drinking at the same rate, but they drank less once they started,” she said. “If your usual pattern was to come home and have a few beers, you would still do that, but you might have one or two instead of four or five.”

A medication that reliably decreases would be of immense value in reducing the harm caused by alcohol abuse, Mitchell said. “If you currently drink seven drinks a night, and we can turn that into two or three, then you’re not only drinking at a level that’s going to harm you less, you’re less likely to harm others, as well. If we could lower the rates of drunk driving, spousal and child abuse and other secondary effects of alcoholism, that would be tremendous.”

They noted that the study corroborates earlier Gallo Center research indicating that alcohol and nicotine act through a common pathway in regions of the brain that provide a sense of pleasure and reward. Varenicline acts as a smoking cessation aid by blocking the pleasant effects of nicotine in the brain.

Few unpleasant or serious side effects were reported, suggesting that the drug can be well tolerated, said Fields. However, the scientists cautioned that the absence of significant side effects might have occurred because subjects were rigorously screened for mental health disorders such as depression, anxiety and suicidal ideation, as well as alcoholism, before the study began. They recommended that the drug be tested for safety and effectiveness in populations with comorbid psychiatric conditions, as well as in treatment-seeking alcohol abusers who do not smoke.

Varenicline is marketed by Pfizer Inc. under the brand name Chantix. The company donated the drug for the study, but did not fund or participate in any part of the research.

The study was published on May 1 in the journal Psychopharmacology.

Explore further: Smoking cessation aide shows promise as alcoholism treatment

More information: www.ncbi.nlm.nih.gov/pubmed/22547331

Related Stories

Smoking cessation aide shows promise as alcoholism treatment

February 15, 2012
A medication commonly used to help people stop smoking may have an unanticipated positive side effect for an entirely different vice: drinking alcohol. A new study by University of Chicago researchers finds that varenicline, ...

Starting smoking cessation medication earlier may make it easier to quit

January 5, 2012
Smokers planning to kick the habit may have more success if they begin using a cessation medication several weeks before they actually try to quit. Those are the results of a clinical trial conducted by researchers at the ...

Benefits of Varenicline (Chantix) may balance certain risks

March 19, 2012
(Medical Xpress) -- The U.S. Food and Drug Administration (FDA) has approved the smoking cessation medication varenicline (Chantix) as an effective aide in helping people quit smoking, including those with cardiovascular ...

Study offers clue as to why alcohol is addicting: Drinking releases brain endorphins

January 11, 2012
(Medical Xpress) -- Drinking alcohol leads to the release of endorphins in areas of the brain that produce feelings of pleasure and reward, according to a study led by researchers at the Ernest Gallo Clinic and Research Center ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.